海特生物 (300683)

Wuhan Hiteck Biological Pharma Co.,Ltd

ASZ

Tags

Contract Research Organization (CXO)New QFII HoldingsQFII Heavy PositionsImmunotherapyInnovative DrugsPharmaceutical ManufacturingGoodwill ImpairmentMicro and Small Cap StocksBelow IPO Price

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 13089.44
  • Circulating A-Shares(W): 12206.46
  • Earnings Per Share(RMB): -1.2100
  • Net Assets Per Share(RMB): 17.0645
  • Operating Revenue(W RMB): 42189.97
  • Total Profit(W RMB): -17187.02
  • Net Profit Attributable to Parent(W RMB): -15809.27
  • Net Profit Growth Rate(%): -297.78
  • Weighted Return on Equity(%): -6.8400
  • Operating Cash Flow Per Share(RMB): -0.5810
  • Undistributed Profit Per Share(RMB): 1.6208
  • Capital Reserve Per Share(RMB): 14.0336

2. Main Business

The main business covers:

  • Production and sales of large molecule biologics, small molecule chemical drugs, active pharmaceutical ingredients (APIs) and pharmaceutical intermediates.
  • Providing CRO, CMO, and CDMO technical services for formulations and APIs to domestic and international pharmaceutical companies.

3. Company Basic Information

  • Company Name: Wuhan Hiteck Biological Pharma Co., Ltd.
  • Listing Date: 2017-08-08
  • Industry: Pharmaceutical Manufacturing
  • Address: Haite Science Park, Wuhan Economic & Technological Development Zone, Hubei Province
  • Website: www.hiteck.com.cn
  • Company Profile：The issuer was established by converting Hiteck Co., Ltd. into a joint stock company. On November 10, 2000, all shareholders of Hiteck Co., Ltd. jointly signed the "Sponsor Agreement for the Establishment of Wuhan Hiteck Biological Pharmaceutical Co., Ltd.", unanimously agreeing to establish Wuhan Hiteck Biological Pharmaceutical Co., Ltd. On November 25, 2000, Hubei Ruidaxin Accounting Firm issued the "Capital Verification Report" (E Rui Hui Shi Yan Zi (2000) No. 68), verifying the sponsors' capital contribution. On November 29, 2000, the Wuhan Economic System Reform Commission issued the document "Reply from the Municipal System Reform Commission on the Establishment of Wuhan Hiteck Biological Pharmaceutical Co., Ltd." (Wu Ti Gai Han [2000] No. 11), approving the overall restructuring of Hiteck Co., Ltd. into a joint stock company, with all shares subscribed by the original shareholders in their original proportions. On November 6, 2003, the Hubei Provincial People's Government issued the document "Approval of the Hubei Provincial People's Government on Confirming the Establishment and Share Capital Structure Adjustment of Wuhan Hiteck Biological Pharmaceutical Co., Ltd." (E Zheng Gu Han [2003] No. 49), confirming the issuer's overall restructuring. On November 30, 2000, Hiteck Biological was registered with the Wuhan Administration for Industry and Commerce and obtained the "Business License of Enterprise Legal Person" (Registration No. 4201141160142), with a registered capital of 60 million yuan. In September 2015, Zhonglian issued the "Asset Appraisal Report for the Retrospective Appraisal Project of Wuhan Hiteck Biochemical Pharmaceutical Co., Ltd. Intending to Change to a Joint Stock Company" (E Zhong Lian Ping Bao Zi [2015] No. 1146), retrospectively appraising the fair value of Hiteck Co., Ltd. as of October 31, 2000, with an assessed net asset value of 61.8922 million yuan. In March 2016, Zhonghuan issued the "Review Note on the Capital Verification Status of Wuhan Hiteck Biological Pharmaceutical Co., Ltd." (Zhong Huan Zhuan Zi (2016) 010051), reviewing the paid-in capital contribution at the time of Hiteck Biological's overall change.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Wuhan Sanjiangyuan Investment Development Co., Ltd. General Legal Person 2520.94 20.65
2 Wuhan Boruile Enterprise Management Co., Ltd. General Legal Person 1479.06 12.12
3 Wuhan Botai Enterprise Development Co., Ltd. General Legal Person 300.00 2.46
4 UBS AG QFII 123.26 1.01
5 China Securities (Hong Kong) Asset Management Co., Ltd. - Client Funds Asset Management Plan 104.71 0.86
6 Huatai Securities Co., Ltd. Broker 88.32 0.72
7 Goldman Sachs & Co. LLC QFII 83.32 0.68
8 GF Innovation Healthcare Two-Year Holding Hybrid Securities Investment Fund A Class Fund 36.35 0.30
9 Chuangjin Hexin Pharmaceutical Consumption Equity Securities Investment Fund A Class Fund 23.68 0.19

5. Concept Sectors

  • Immunotherapy
  • CXO Concept
  • Innovative Drugs
  • QFII Heavy Holdings
  • Consecutive Losses
  • Below IPO Price
  • Goodwill Impairment
  • QFII New Entry
  • Micro-Cap Stocks

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information